Supplies of Biocon’s partnered interchangeable insulin glargine biosimilar, Semglee, buoyed earnings momentum for the Indian firm’s biosimilars business in the fiscal third quarter, with “significant uptake” in store in view of several commercial arrangements already in place in the US.
Biocon Biologics’ deputy CEO Shreehas Tambe highlighted recent gains made by partner Viatris for the product, which received preferred...







